Observational Real-World Study to Assess Clinical Characteristics and Device Satisfaction in Patients with COPD Treated with Glycopyrrolate/eFlow® CS
Judith J Stephenson,1 Carole Dembek,2 Amanda Caldwell-Tarr,3 Rebecca M Conto,1 Mark Paullin,1 Edward M Kerwin4 1HealthCore Inc., Wilmington, DE, USA; 2Sunovion Pharmaceuticals Inc., Marlborough, MA, USA; 3HealthCore Inc., Watertown, MA, USA; 4Clinical Research Institute of Southern Oregon, Medford,...
Main Authors: | Stephenson JJ, Dembek C, Caldwell-Tarr A, Conto RM, Paullin M, Kerwin EM |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2020-07-01
|
Series: | International Journal of COPD |
Subjects: | |
Online Access: | https://www.dovepress.com/observational-real-world-study-to-assess-clinical-characteristics-and--peer-reviewed-article-COPD |
Similar Items
-
In Vitro Effect of Different Airflow Rates on the Aerosol Properties of Nebulized Glycopyrrolate in the eFlow® Closed System and Tiotropium Delivered in the HandiHaler®
by: Jill A. Ohar, et al.
Published: (2020-08-01) -
Dose selection for glycopyrrolate/eFlow® phase III clinical studies: results from GOLDEN (Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer) phase II dose-finding studies
by: James F. Donohue, et al.
Published: (2017-12-01) -
Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate
by: Ohar JA, et al.
Published: (2020-05-01) -
Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate [Corrigendum]
by: Ohar JA, et al.
Published: (2021-05-01) -
Effect of background long-acting beta2-agonist therapy on the efficacy and safety of a novel, nebulized glycopyrrolate in subjects with moderate-to-very-severe COPD
by: Kerwin EM, et al.
Published: (2018-09-01)